Literature DB >> 8826882

In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis.

D Gottardi1, A Alfarano, A M De Leo, A Stacchini, M Aragno, A Rigo, D Veneri, R Zanotti, G Pizzolo, F Caligaris-Cappio.   

Abstract

This study further investigated the mechanisms that control apoptosis in leukaemic CD5+ B cells, and focused on the Bcl-2 gene family. The pattern of expression of Bcl-2, Bcl-xL, Bcl-xS and Bax genes, selected because of their interrelated role in the control of apoptosis, was analysed in a series of CD5+ B-cell chronic lymphoid leukaemias. Cells from 34 patients with chronic lymphoid leukaemia of B-cell type (23 B-chronic lymphocytic leukaemia (B-CLL) and 11 mantle cell lymphoma (MCL) in leukaemic phase) were investigated. High levels of Bcl-2 mRNA were observed by Northern blot and high levels of Bcl-2 protein were detected by cytofluorograph analysis with a specific monoclonal antibody (MAb) in all cases. Strong Bax expression was detected by RT-PCR in 20/23 B-CLL cases; Bax was also observed in 8/11 MCL in leukaemic phase with variable degree of intensity. In both B-CLL and MCL samples the presence of Bax protein was confirmed by cytofluorograph analysis. RT-PCR detected high levels of Bcl-xL in 16/23 B-CLL and in 8/11 MCL in leukaemic phase, whereas Bcl-xS was detectable in low to trace amounts respectively in 13/23 B-CLL and in 6/11 MCL in leukaemic phase. According to the functional role of Bcl-2, Bcl-xL, Bcl-xS and Bax, these data indicate that the pattern of Bcl-2 family genes expression in leukaemic CD5+ B cells is skewed toward prevention of apoptosis and may thus favour the relentless accumulation of CD5+ leukaemic B cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8826882     DOI: 10.1046/j.1365-2141.1996.d01-1856.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  16 in total

1.  Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL.

Authors:  Jennifer S Carew; Steffan T Nawrocki; Yelena V Krupnik; Kenneth Dunner; David J McConkey; Michael J Keating; Peng Huang
Journal:  Blood       Date:  2005-09-06       Impact factor: 22.113

2.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Authors:  Kumudha Balakrishnan; Christine M Stellrecht; Davide Genini; Mary Ayres; William G Wierda; Michael J Keating; Lorenzo M Leoni; Varsha Gandhi
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

3.  An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.

Authors:  Sayer Al-Harbi; Brian T Hill; Suparna Mazumder; Kamini Singh; Jennifer Devecchio; Gaurav Choudhary; Lisa A Rybicki; Matt Kalaycio; Jaroslaw P Maciejewski; Janet A Houghton; Alexandru Almasan
Journal:  Blood       Date:  2011-07-19       Impact factor: 22.113

Review 4.  Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.

Authors:  Leyte L Winfield; Florastina Payton-Stewart
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

Review 5.  Genetics and molecular biology of chronic lymphocytic leukemia.

Authors:  Dennis A Carney; William G Wierda
Journal:  Curr Treat Options Oncol       Date:  2005-05

Review 6.  Inflammation and survival pathways: chronic lymphocytic leukemia as a model system.

Authors:  Lisa S Chen; Kumudha Balakrishnan; Varsha Gandhi
Journal:  Biochem Pharmacol       Date:  2010-08-07       Impact factor: 5.858

7.  Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells.

Authors:  Kumudha Balakrishnan; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2008-06-19       Impact factor: 22.113

8.  Bcl-2 level as a biomarker for 13q14 deletion in CLL.

Authors:  Heba A Degheidy; Shahinaz M Gadalla; Mohammed Z H Farooqui; Fatima Abbasi; Diane C Arthur; Steven R Bauer; Wyndham H Wilson; Adrian Wiestner; M A Stetler-Stevenson; Gerald E Marti
Journal:  Cytometry B Clin Cytom       Date:  2013-05-14       Impact factor: 3.058

9.  Surface expression of Bcl-2 in chronic lymphocytic leukemia and other B-cell leukemias and lymphomas without a breakpoint t(14;18).

Authors:  Brian A McCarthy; Erin Boyle; Xue Ping Wang; Dorothy Guzowski; Santanu Paul; Rosa Catera; Joshua Trott; Xiao-jie Yan; Carlo M Croce; Rajendra Damle; Sophia Yancopoulos; Bradley T Messmer; Martin Lesser; Steven L Allen; Kanti R Rai; Nicholas Chiorazzi
Journal:  Mol Med       Date:  2008 Sep-Oct       Impact factor: 6.354

10.  Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia.

Authors:  Maria Ilaria Del Principe; Michele Dal Bo; Tamara Bittolo; Francesco Buccisano; Francesca Maria Rossi; Antonella Zucchetto; Davide Rossi; Riccardo Bomben; Luca Maurillo; Mariagiovanna Cefalo; Giovanna De Santis; Adriano Venditti; Gianluca Gaidano; Sergio Amadori; Paolo de Fabritiis; Valter Gattei; Giovanni Del Poeta
Journal:  Haematologica       Date:  2015-11-12       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.